Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 8, Pages 2212-2217Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1525795113
Keywords
aging; myostatin; muscle mass; insulin resistance; sarcopenia
Categories
Funding
- National Institutes of Health [R01 DK-40936, R24 DK-085638, U24 DK-059635, P30 DK-45735, R01 AG-23686, K01 DK-099402, T32 GM-007205, F30 DK-104596]
- Atara Pharmaceuticals
- American Diabetes Association (ADA)-Distinguished Clinical Investigator Award
- ADA-Merck Mentor Based Clinical/Translational Science Postdoctoral Fellowship Award from the American Diabetes Association [1-14-10 Merck]
Ask authors/readers for more resources
Sarcopenia, or skeletal muscle atrophy, is a debilitating comorbidity of many physiological and pathophysiological processes, including normal aging. There are no approved therapies for sarcopenia, but the antihypertrophic myokine myostatin is a potential therapeutic target. Here, we show that treatment of young and old mice with an anti-myostatin antibody (ATA 842) for 4 wk increased muscle mass and muscle strength in both groups. Furthermore, ATA 842 treatment also increased insulin-stimulated whole body glucose metabolism in old mice, which could be attributed to increased insulin-stimulated skeletal muscle glucose uptake as measured by a hyperinsulinemic-euglycemic clamp. Taken together, these studies provide support for pharmacological inhibition of myostatin as a potential therapeutic approach for age-related sarcopenia and metabolic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available